<DOC>
	<DOCNO>NCT02666989</DOCNO>
	<brief_summary>Open label placebo treatment try irritable bowel syndrome ( Kaptchuk et al , 2010 ) , three week open label placebo prove superior wait-listed control group . Another pilot study demonstrate efficacy treat child suffer ADHD open label placebo treatment ( Sandler &amp; Bodfish , 2007 ) . Recent work show placebo openly give significant analgesic effect acute migraine ( Kam-Hansen et al , 2014 ) experimentally-induced pain ( Schafer al , 2015 ) . A preliminary attempt treat depression open label placebo prove feasibility study , small brief conclusive result ( Kelley et al , 2012 ) . We provide protocol study assess effect open label placebo treatment depression .</brief_summary>
	<brief_title>Open-Label Placebo Treatment Depression</brief_title>
	<detailed_description>participant recruit advertisement traditional on-line press , via mental health care worker local clinic . The psychiatrist study team also option access wait list outpatient clinic Shalvata Mental Health Center , recruit patient ( 's intake appointment outpatient clinic expect take place 2 month ) study via phone face face clinic . If subject already take antidepressant treatment recruit immediately study . If subject take antidepressant treatment , examination diagnose depression , investigator advice approach outpatient clinic start take antidepressant medication . If subject refuse use medication recruit study medication-free . Patients invited participate study follow word use : `` invite participate novel mind-body study harness placebo effect treatment depression . In study recieve , either immediately follow wait period , placebo ( inert ) tablet . There active component tablet , good chance alleviate depressive symptom . Furthermore , recent scientific evidence suggest placebo tablet initiate healthy response even person know placebo '' . Each participant provide sign informed consent . Each subject receive letter personal physician psychiatrist community/hospital . Additionally , study team also contact personal physician inform study . Subjects continue psychiatric follow-up treatment usual whole period study . If study team recognize suicidal deterioration personal physician/psychiatrist notify immediately via phone . If subject currently without psychiatric follow-up , examine assessment point ( every 2 week ) study protocol one physician study team . Before first session , participant randomize one two possible intervention : either 8 week open label placebo , 4 week waitlist follow four week open label placebo . The randomization procedure stratify account two group subject : currently stable dose medication , currently receive medication . Therefore , time subject one group randomize one two intervention ( open label placebo wait list ) , next subject group assign intervention . By method , obtain proportion medicate unmedicated patient two intervention arm . At first session , participant positive expectation commitment promote discuss participant follow four point : ( ) research , placebo find safe term side-effects roughly 80 % effective antidepressant ; ( b ) recent research suggest patient benefit placebo even know take placebo ; ( c ) placebo appear promote automatic self-healing process , possibly classical conditioning ; take tablet cause release neurotransmitter activate specific region brain related depression ] ( ) placebo-treated patient adhere tablet regimen well outcomes , therefore placebos take faithfully , ( e ) positive expectation enhance placebo effect , perfectly normal doubt disbelief wo n't interfere effect . At end first session , researcher open envelope reveal researcher participant group latter randomize . Both treatment arm no-treatment control identical patient-provider interaction equal length . Those waitlist group encourage continue study . The placebo color tablet . Each participant enjoin take two capsule morning , two evening . After four week , placebo group continue second four week period placebo treatment , waitlist group start receive 4 week placebo treatment .</detailed_description>
	<mesh_term>Depressive Disorder</mesh_term>
	<mesh_term>Depression</mesh_term>
	<mesh_term>Depressive Disorder , Major</mesh_term>
	<criteria>. Major Depressive Episode accord DSMV ii . Mild Moderate depression ( 8 &gt; HAMD17 &lt; 24 ) iii . Receiving antidepressant medication change medication last two week receive antidepressant medication . Psychotic depression ii . Agitated depression iii . Bipolar depression iv . Current suicidality past suicide attempt v. Current drug alcohol abuse vi . Psychotic disorder vii . Drug and/or alcohol abuse</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>80 Years</maximum_age>
	<verification_date>January 2016</verification_date>
	<keyword>Depression</keyword>
	<keyword>Placebo</keyword>
	<keyword>Open-label</keyword>
	<keyword>Clinical practice</keyword>
</DOC>